Oscar Health CEO talks the company's path to profitability

This episode explores Oscar Health's Q3 performance and future growth strategy, featuring an interview with CEO Mark Bertolini. Against the backdrop of a 16% share price surge following strong Q3 results and upwardly revised full-year guidance, Bertolini discusses the company's strategic shift towards profitability by 2024. He explains that 2023 involved internal restructuring to optimize expenses and capital generation, achieving three quarters of profitability. More significantly, the discussion pivots to Oscar Health's expansion plans, including adding 165 new counties across eleven states and aiming for nearly 20% membership and revenue growth in 2024 within the ACA market. Bertolini highlights their focus on a digital-first approach and plans to expand into new markets like Medicare Advantage, aiming to streamline the process by partnering directly with health systems, potentially reducing healthcare costs. For instance, he points out the high profit margins of current insurance companies in Medicare Advantage and suggests shifting these margins to health systems could improve service and lower costs. Finally, the conversation touches on the implications of widespread Ozempic use, with Bertolini emphasizing the importance of lifestyle changes alongside medication to avoid escalating healthcare costs. This discussion reveals Oscar Health's ambitious growth strategy and its potential impact on the future of healthcare costs and accessibility.